Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vitro and in vivo preclinical characterization of a preconceptionally administered maternal vaccine against severe neonatal Escherichia coli K1 infections

ABSTRACT: In vitro and in vivo preclinical characterization of a preconceptionally administered maternal vaccine against severe neonatal Escherichia coli K1 infections

PROVIDER: PRJNA1058490 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

In vitro and in vivo preclinical characterization of a preconceptionally administered maternal vaccine against severe neonatal Escherichia coli K1 infections

Project description:Preterm birth is currently the leading cause of neonatal morbidity and mortality. Genetic, immunological and infectious causes are suspected. Preterm infants have a higher risk of severe bacterial neonatal infections, most of which are caused by Escherichia coli an in particular E. coli K1strains. Women with history of preterm delivery have a high risk of recurrence and therefore constitute a target population for the development of vaccine against E. coli neonatal infections. Here, we characterized the immunological, microbiological and protective properties of a live attenuated vaccine candidate in adult female mice and their pups against after a challenge by K1 and non-K1 strains of E. coli. Our results show that the E. coli K1 E11 aroA vaccine induces strong immunity, driven by polyclonal bactericidal antibodies. In our model of meningitis, pups born to mothers immunized before mating were well protected against various K1 and non-K1 strains of E. coli. Given the very high mortality rate and the neurological sequalae associated with neonatal E. coli K1 meningitis, our results constitute preclinical proof of concept for the development of a live attenuated vaccine against severe E. coli infections in women at risk of preterm delivery.

2024-01-02 | GSE252194 | GEO

A live attenuated vaccine to prevent severe neonatal Escherichia coli K1 infections.

Project description:Preterm birth is currently the leading cause of neonatal morbidity and mortality. Genetic, immunological and infectious causes are suspected. Preterm infants have a higher risk of severe bacterial neonatal infections, most of which are caused by Escherichia coli an in particular E. coli K1strains. Women with history of preterm delivery have a high risk of recurrence and therefore constitute a target population for the development of vaccine against E. coli neonatal infections. Here, we characterize the immunological, microbiological and protective properties of a live attenuated vaccine candidate in adult female mice and their pups against after a challenge by K1 and non-K1 strains of E. coli. Our results show that the E. coli K1 E11 ∆aroA vaccine induces strong immunity, driven by polyclonal bactericidal antibodies. In our model of meningitis, mothers immunized prior to mating transfer maternal antibodies to pups, which protect newborn mice against various K1 and non-K1 strains of E. coli. Given the very high mortality rate and the neurological sequalae associated with neonatal E. coli K1 meningitis, our results constitute preclinical proof of concept for the development of a live attenuated vaccine against severe E. coli infections in women at risk of preterm delivery.

| S-EPMC11001983 | biostudies-literature

Next Generation Sequencing of transfected NC K1 cells and transfected si-NEAT1_2 K1 cells

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of transfected NC K1 cells and transfected si-NEAT1_2 K1 cells. The goals of this study are to analysis the different mRNA expression between transfected NC K1 cells and transfected si-NEAT1_2 K1 cells. Quantitative reverse transcription polymerase chain reaction (qRT–PCR) methods and to evaluate protocols for optimal high-throughput data analysis. We performed mRNA-seq in the NEAT1_2 knockdown group and NC group in the K1 cell line. We found that after knockdown of NEAT1_2, 615 mRNAs were upregulated and 2364 mRNAs were downregulated.

2020-12-05 | GSE159905 | GEO

Bacillus sp. K1 strain:k1 | isolate:k1

Project description:Bacillus sp. K1 strain:k1 | isolate:k1 Genome sequencing

| PRJNA816635 | ENA

circRNA maps in AhR antagonist treated K1 cells

Project description:High-throughput data analysis was performed to identify the differentially expressed circRNAs in K1 control cell and AhR antagonist treated K1 cells. In total, 45 differentially expressed circRNAs were found.

2021-11-30 | GSE188657 | GEO

Exiguobacterium sp. K1 strain:K1

Project description:Exiguobacterium sp. K1 strain:K1 Genome sequencing and assembly

| PRJNA882588 | ENA

Campylobacter jejuni K1 strain:K1

Project description:Campylobacter jejuni K1 strain:K1 Genome sequencing and assembly

| PRJNA212385 | ENA

Imtechella halotolerans K1 strain:K1

Project description:Imtechella halotolerans K1 strain:K1 Genome sequencing and assembly

| PRJNA112533 | ENA

Exiguobacterium sibiricum strain:K1 | isolate:K1

Project description:Exiguobacterium sibiricum strain:K1 | isolate:K1 Genome sequencing

| PRJNA761004 | ENA

ChIA-PET from K1 (ENCSR314HAC)

Project description:RAD21 ChIA-PET in human K1 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2019-03-03 | GSE127025 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data